Pamela L. Clemens
Johnson & Johnson (United States)(US)
Publications by Year
Research Areas
Multiple Myeloma Research and Treatments, Peptidase Inhibition and Analysis, Monoclonal and Polyclonal Antibodies Research, Lung Cancer Treatments and Mutations, Protein Degradation and Inhibitors
Most-Cited Works
- → Subcutaneous versus intravenous daratumumab in patients with relapsed or refractory multiple myeloma (COLUMBA): a multicentre, open-label, non-inferiority, randomised, phase 3 trial(2020)233 cited
- → Effects of daratumumab on natural killer cells and impact on clinical outcomes in relapsed or refractory multiple myeloma(2017)220 cited
- → Daratumumab plus carfilzomib and dexamethasone in patients with relapsed or refractory multiple myeloma(2019)131 cited
- → Monitoring multiple myeloma patients treated with daratumumab: teasing out monoclonal antibody interference(2016)117 cited
- → Subcutaneous delivery of daratumumab in relapsed or refractory multiple myeloma(2019)115 cited
- → Phase 1/2 study of daratumumab, lenalidomide, and dexamethasone for relapsed multiple myeloma(2016)110 cited
- → Subcutaneous Versus Intravenous Amivantamab, Both in Combination With Lazertinib, in Refractory Epidermal Growth Factor Receptor–Mutated Non–Small Cell Lung Cancer: Primary Results From the Phase III PALOMA-3 Study(2024)98 cited
- → Daratumumab monotherapy for patients with intermediate-risk or high-risk smoldering multiple myeloma: a randomized, open-label, multicenter, phase 2 study (CENTAURUS)(2020)95 cited
- → Pharmacokinetics of Daratumumab Following Intravenous Infusion in Relapsed or Refractory Multiple Myeloma After Prior Proteasome Inhibitor and Immunomodulatory Drug Treatment(2016)82 cited
- → Clinical Implications of Complex Pharmacokinetics for Daratumumab Dose Regimen in Patients With Relapsed/Refractory Multiple Myeloma(2016)67 cited